Compare
NextCure, Inc. vs Lifevantage Corp vs Tvardi Therapeutics, Inc. vs Nuvectis Pharma, Inc.
| Latest fiscal year | NextCure, Inc. NXTC | Lifevantage Corp LFVN | Tvardi Therapeutics, Inc. TVRD | Nuvectis Pharma, Inc. NVCT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $182.59M | n/a | n/a |
| Revenue growth (YoY) | n/a | -20.1% | n/a | n/a |
| Gross margin | n/a | 77.6% | n/a | n/a |
| Operating margin | n/a | 3.3% | n/a | n/a |
| Net margin | n/a | 2.8% | n/a | n/a |
| Net income | -$55.84M | $5.07M | -$18.21M | -$26.44M |
| EPS (Diluted) | -$19.65 | $0.40 | -$3.26 | -$1.32 |
| Operating cash flow | -$49.61M | $10.24M | -$23.50M | -$16.01M |
| Free cash flow | n/a | $6.67M | n/a | n/a |
| Cash & equivalents | $25.98M | n/a | $20.73M | $31.63M |
| Total assets | $50.18M | $62.11M | $32.07M | $31.71M |
| Total liabilities | $15.24M | $28.52M | $11.13M | $13.30M |
| Shareholders' equity | $34.94M | $33.59M | $20.95M | $18.41M |
| Return on year-end equity | -159.8% | 15.1% | -87.0% | -143.6% |
| Shares outstanding | 3.51M | 12.52M | 9.38M | 25.68M |
Revenue, most recent five fiscal years
| Fiscal year | NextCure, Inc. | Lifevantage Corp | Tvardi Therapeutics, Inc. | Nuvectis Pharma, Inc. |
|---|---|---|---|---|
| Latest | $22.38M Ended 2020-12-31 | $182.59M Ended 2026-06-30 | $7.14M Ended 2024-12-31 | n/a |
| 1 year earlier | $6.35M Ended 2019-12-31 | $228.53M Ended 2025-06-30 | $20.97M Ended 2023-12-31 | n/a |
| 2 years earlier | n/a | $200.16M Ended 2024-06-30 | $41.87M Ended 2022-12-31 | n/a |
| 3 years earlier | n/a | $213.40M Ended 2023-06-30 | $23.03M Ended 2021-12-31 | n/a |
| 4 years earlier | n/a | $206.36M Ended 2022-06-30 | $135.08M Ended 2020-12-31 | n/a |